Equi­l­li­um's im­muno-in­flam­ma­to­ry drug wins FDA's or­phan drug sta­tus; Van­da sues FDA for man­dat­ing lengthy dog study

→ San Diego-based Equi­l­li­um has nabbed an or­phan drug des­ig­na­tion for EQ001 on the verge of be­gin­ning a Phase Ib/II for the im­muno-in­flam­ma­to­ry drug. Al­so known as itolizum­ab, the drug was in-li­censed from In­dia’s Bio­con, which sells it in the coun­try as a pso­ri­a­sis treat­ment. Equi­l­li­um $EQ, how­ev­er, is fo­cus­ing its US clin­i­cal work on the pre­ven­tion and treat­ment of acute graft-ver­sus-host dis­ease — a strat­e­gy that has al­lowed it to skip fi­nanc­ing rounds and jump straight in­to an IPO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER